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Recent advances in biomedical research in cancer immunotherapy have identified the use 
of an oxidative stress-based approach to treat cancers, which works by inducing 
immunogenic cell death (ICD) in cancer cells. Since the anti-cancer effects of non-thermal 
plasma (NTP) are largely attributed to the reactive oxygen and nitrogen species that are 
delivered to and generated inside the target cancer cells, it is reasonable to postulate that 
NTP would be an effective modality for ICD induction. NTP treatment of tumors has been 
shown to destroy cancer cells rapidly and, under specific treatment regimens, this leads 
to systemic tumor-specific immunity. The translational benefit of NTP for treatment of 
cancer relies on its ability to enhance the interactions between NTP-exposed tumor cells 
and local immune cells which initiates subsequent protective immune responses. This 
review discusses results from recent investigations of NTP application to induce 
immunogenic cell death in cancer cells. With further optimization of clinical devices and 





Cancer and conventional therapies: 
Cancer development is partly attributed to cells acquiring multiple mutations that 
remain unrecognized by the immune system due to low immunogenicity of these mutated 
cells. Failure of the immune system to recognize cancer cells contributes to cancer 
progression by selecting for tumor cells that can survive in an immunocompetent host. 
Unchecked growth is further facilitated within the tumor microenvironment by the 
production of immunosuppressive factors by these cancerous cells, stromal cells, and 
local immune cells. [1-3]. To successfully check the development and progression of 
cancer, the innate and adaptive immune system must act together to identify and destroy 
mutated cells [1]. The innate arm of the immune system generates a rapid, non-specific 
inflammatory response on recognition of a “foreign” cell (mutated) which serves to initiate 
development of specific immune responses. The innate cells have the difficult job of 
differentiating between normal cells (self) and mutated cells (altered mutated self), often 
a key step in the failure of immune recognition. The adaptive arm of the immune system, 
on the other hand, allows for specific immunity to mutated cells via T cells, but takes days 
to weeks to develop. It is the T lymphocytes that selectively destroy cancerous cells that 
carry the specific mutation throughout the body. Furthermore, immunologic memory, the 
hallmark of the adaptive immune system, allows for a more rapid immune response upon 
re-exposure to a specific antigen that defines its “foreignness” [4]. 
 
Modern cancer treatment typically entails a multimodal approach involving a 
combination of systemic chemotherapies, surgery, and radiation; it is associated with a 
broad spectrum of inherent toxicities and in many cases, only modest patient survival. The 
evolution of immunotherapeutic treatment strategies has offered newer treatment 
modalities for cancer patients with better clinical outcomes. These strategies are based 
on methods that break immune tolerance of self-antigens (or ‘altered mutated self’) to 
 4 
overcome ignorance and tolerance to potential antigenic targets on cancer cells as a way 
to destroy tumor cells by immunological mechanisms, hence improving selectivity and 
reducing toxicity[5, 6]. Recent historic advances in immunotherapy highlighted in this 
review underscore our continued quest for novel approaches to the treatment of cancer 
[7-11]. 
 
Non-thermal plasma in cancer therapy 
Non-thermal plasma (NTP), also known as cold atmospheric plasma or non-
equilibrium, atmospheric pressure plasma, has emerged as a promising anti-cancer 
approach. NTP is formed by the application of an electric field to ionize surrounding gas 
(ambient air or a specific gas), creating a discharge consisting of charged molecules, 
ultraviolet light, reactive oxygen species (ROS), and neutral molecules [12, 13] Mounting 
evidence demonstrates that NTP can change the oxidative status of cells through 
stimulation of intracellular ROS production [14, 15]. ROS are known to influence multiple 
signaling pathways regulating cell processes including proliferation, differentiation, and 
cell death [16]. Because NTP has the advantage of being a controlled source of 
incremental ROS, it is therefore being employed for the treatment of various diseases, 
including cancer. Two distinct methods are used to generate NTP [13, 15, 17-19]. 
Dielectric barrier discharge (DBD) devices generate plasma directly on the treatment 
target while plasma jets generate the bulk of the plasma remotely and utilize a gas, such 
as helium or argon, for transport of plasma components to the treatment target [13, 20-
23]. The two main strategies employed for experimental, biomedical delivery of plasma 
involve (1) direct exposure of cultured cells in vitro or tissue in vivo or, more recently, (2) 
indirect exposure to plasma components using plasma-activated liquids in standard cell 
culture for in vitro studies or via perfusion of affected organs [13]. The anti-cancer effects 
of indirectly and directly applied NTP appear to be similar. Direct treatment exposes the 
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target tissue to all the components of plasma. Yan et al demonstrated that directly applied 
NTP induced an “activation” state, resulting in increased sensitivity of cells to ROS and 
RNS [24]. With indirect treatment, active species dissolve into a liquid when exposed to 
plasma from different sources. The “treatment dose” is determined by time of plasma-
exposure of the liquid as well as the period for which the cells or tissue is allowed to remain 
in contact with this liquid. While the differences between the interaction of NTP with liquid 
media (indirect) or the skin (direct) are complex and not fully clear, an important distinction 
between the two treatment modalities is the presence of short lived reactive species such 
as OH during direct treatment [25]. These short lived species may trigger production of 
intracellular, long lived reactive species such as H2O2, potentially resulting in H2O2-
mediated lymphocyte activation[26]. In a study comparing indirect and direct application 
of NTP against metastatic melanoma, Saadati et al demonstrated significantly greater 
cancer cell death and reduction in tumor growth with direct treatment [25]. In the same 
study, they recognized the potential advantage of plasma activated liquids for the 
treatment of tumors deeper than skin level in combination with chemotherapy [25]. Other 
studies have demonstrated that application of plasma-treated medium decreases 
peritoneal tumor burden in mice and prolongs survival [27-29]. Although direct treatment 
with NTP is more effective than indirect treatment, indirect treatment is believed to be 
associated with less toxicity [24-26, 30]. 
 
NTP, whether generated from DBD or jet-based devices, results in somewhat 
selective toxicity to cancer cells both in vitro and in vivo (Table 1), although the subject of 
selectivity is open to question. In vitro, anticancer efficacy of NTP has been demonstrated 
in several distinct, established cancer cell lines: brain cancer, skin cancer, breast cancer, 
colorectal cancer, lung cancer, cervical cancer, leukemia, head and neck cancer, and 
hepatoma (Table 1) [13, 31-44]. The majority (70%) of these studies employed jet devices 
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[13]. In a pioneering study demonstrating cancer growth inhibition in vivo, Vandamme et 
al. directly applied NTP to subcutaneous U87-Luc malignant glioma tumors in nude mice. 
They reported safety of their treatment protocol as well as anti-tumor activity [17, 45, 46]. 
Subsequent in vivo investigations looking at NTP for treatment of subcutaneous xenograft 
tumors or orthotopic melanomas in mice have consistently demonstrated tumor cell 
death/growth inhibition and increased animal survival [13, 37, 45-53]. Other mouse model 
studies have demonstrated anticancer capacity of plasma in bladder cancer [37], head 
and neck cancer [48], ovarian cancer [54], pancreatic cancer [47, 55], neuroblastoma [49], 
melanoma [51, 52], and breast cancer [50]. Local tumor regression was in seen in all 
cases, and in some cases, improved animal survival was documented. Since these 
studies employed different NTP devices, it is difficult to judge if the inconsistent animal 
survival is because of differences in tumor types or the nature and delivery of plasma 
generated. Furthermore, studies variously used immunocompetent or 
immunocompromised animals making it difficult to delineate the contribution of immune 
pathways in NTP efficacy. Finally, the mechanism of tumor cell death or the organismal 
level pathways activated were not investigated in depth in the aforementioned studies. 
These topics are subjects of ongoing studies in many labs around the world. 
 
Anti-cancer mechanism of non-thermal plasma 
It is fair to state that the anti-cancer mechanism of NTP is incompletely understood. 
The effects and importance of individual NTP components (radiation, electromagnetic 
fields, and reactive species) in cancer cell death continue to be investigated and it seems 
unlikely that any single component will emerge as the critical factor. Nevertheless, the 
direct anti-cancer potential of NTP has been ascribed to a rise in reactive species inside 
cancer cells, changing the cellular redox balance. Although there is evidence that other 
components of NTP contribute to its therapeutic role, the cocktail of RONS, both 
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originating from NTP and those produced by NTP-exposed cells, are postulated to be the 
most important active constituent for the effects on cancer cells [56]. The resulting 
challenge to the cancer cell’s anti-oxidant response ultimately pushes the cell toward cell 
cycle arrest and apoptosis [13]. While other therapies function through a similar pathway, 
one of the primary advantages of NTP is selective toxicity against cancer cells by the 
ability to controllably deliver ROS such that there is relatively little impact on non-
cancerous cells in the tumor microenvironment and the surrounding tissues. Although 
defining the mechanism of selectivity against cancer cells continues to be a key challenge 
in the field, it has been attributed to greater rise in ROS in cancer cells compared to normal 
cells [13, 57, 58]. 
Another challenge in the understanding of NTP mechanism of action is the 
penetration of plasma components in treated tissue. The physical effects of plasma are 
believed to be only a few hundred micrometers, but biological effects been observed 
several millimeters deep within tissue. The biological effects of NTP extend beyond the 
superficial layers, evidenced by significant shrinkage of subcutaneous tumors with 
diameters of ~ 1 cm following surface NTP treatment [17, 47, 49]. However, the specific 
plasma-produced RONS delivered to biological targets and the depth to which they are 
delivered remain uncertain. Furthermore, there remain questions as to how RONS interact 
with various components of the target tissue [59]. Experimental and simulation studies 
have shown that deeper in the tissue (greater than millimeters below the surface), most 
plasma-derived RONS are converted to more stable RONS with longer half-lives [60-64]. 
Since the initial interaction between plasma-derived RONS and the tissue remains largely 
unknown, the reasons why biological effects permeate beyond physical reach of NTP 
components remain a key area of research interest. 
 
Recent studies suggest that immune activation may also contribute to NTP’s anti-
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cancer effects [1, 65-67]. In that context, the efficacy of plasma treatment, with respect to 
life-expectancy, was greater in studies performed on immunocompetent mice compared 
to those using immunodeficient mice. These particular findings warrant further 
investigations of the immunogenic capacity of plasma [1, 37, 49]. More recently, studies 
have demonstrated macrophage augmentation and immunogenic cell death in response 
to NTP-induced ROS and reactive nitrogen species (RNS) [65-70]. Importantly, Mizuno 
et. al. demonstrated abscopal effects of NTP on B16-F10 melanoma growth. This was 
evidenced by tumor growth suppression at sites distal to site of NTP treatment in CD2F1 
and C57BL/6 murine models [71], further endorsing the immunogenic potential of NTP. It 
is important to reiterate that more in depth longitudinal studies of plasma interaction with 
cancers, especially in animal models, are critically needed to define the anti-cancer 
mechanism of NTP. 
 
Recent advances in immunotherapy for cancer: 
Cancer immunotherapy has gained popularity and momentum in recent years. In 
fact, the 2018 Nobel Prize in Physiology or Medicine was awarded to cancer 
immunotherapy researchers James P. Allison and Tasuku Honjo for their historic work on 
immune check-point inhibitors. Indeed, the ultimate goal of cancer immunotherapy is to 
induce immunologic memory against tumor cells. However, it remains challenging to 
induce immunologic memory against a tumor cell that continues to acquire mutations, thus 
changing its antigenic nature and allowing for immune escape. Allison and Honjo 
established that by inhibiting cellular “off” signals [i.e., cytotoxic T lymphocyte associated 
protein 4 (CTLA-4), which is vital for maintaining homeostasis during normal immune 
responses, and programmed death protein 1 (PD-1) of T lymphocytes (the foot soldiers of 
the immune system)], the T lymphocyte response would be unleashed to eliminate tumor 
cells. Today, ipilimumab, the antibody to CTLA-4, is an FDA approved treatment for 
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melanoma [9, 10] (Figure 1a). Furthermore PD-1 blocking agents (nivolumab, 
pembrolizumab, durvalumab, atezolizumab and avelumab) remove the brakes on T cells, 
allowing them to effect tumor regression and improved survival in patients with advanced 
and metastatic tumors [11] (Figure 1b). 
 
Chimeric antigen receptors (CARs) are another novel class of drugs in the field of 
cancer immunotherapy. CAR is a fusion protein consisting of an antigen recognition 
domain and a T cell signaling domain. It is the antigen recognition domain that recognizes 
and binds tumor proteins to provide the specificity against the tumor being targeted. T 
cells can be genetically engineered in the laboratory to express specific CARs against 
cancer cells, resulting in direct, targeted anti-cancer immune response. The signaling 
domain initiates killing pathways once the antigen recognition domain is bound to the 
antigen – in this case, the cancer cell expressing the antigen. Two CAR T cell therapy 
agents are now approved for the treatment of hematologic malignancies for pediatric acute 
lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL) [72, 73] 
(Figure 1c).  
 
While there have been significant breakthroughs made in the field of cancer 
immunotherapy, these agents have, at times, been subject to side effects and lack of 
success against all tumors. Many patients are refractory to these treatments and others 
develop resistance. They are also extremely expensive and time intensive to generate. 
Importantly, these advances provide strong support for the importance of harnessing the 
immune system for cancer control as a vital part of cancer treatment regimens. They 
provide a platform for continued development of novel immunotherapeutic strategies. 
 
Rationale for use of physical methods in immunotherapy 
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In addition to these immunotherapeutic agents, more general, non-specific 
physical methods known to activate the immune system, including photodynamic therapy 
(PDT) and radiation therapy (RT), have been employed to treat cancer [1]. The anti-cancer 
properties of PDT are attributed to the combination of non-toxic photosensitizers and 
visible light, which, upon interaction with oxygen, produce cytotoxic ROS that kill malignant 
cells via apoptosis/necrosis, shut down tumor vasculature, and subsequently stimulate the 
immune system [74]. Immunogenicity of PDT is attributed to induction of acute 
inflammation and the release of cytokines/stress response proteins, with the resultant 
leukocyte influx contributing to tumor destruction and, importantly, immune memory [1, 74, 
75]. RT is part of the traditional anti-cancer armament being used for tumor regression 
through direct cytotoxicity. In recent years, the immuno-stimulatory potential of RT, 
another redox stress-based therapy, in conjunction with other immunotherapeutic agents 
has been and continues to be investigated in ongoing clinical trials involving several types 
of cancer [1, 76, 77]. 
 
Immunogenic cell death-based immunotherapy and rationale for plasma-based 
immunotherapy 
Immunogenic cell death (ICD), initially described by the Kroemer/Zitvogel model, 
is a form of programmed cell death that has the potential to stimulate the adaptive immune 
system [67, 78, 79]. Figure 2a demonstrates the proposed role of NTP in induction of ICD. 
Various anti-cancer agents, including select systemic chemotherapies, PDT, RT, high 
hydrostatic pressure, small molecules, and oncolytic viruses, have been described as 
having the capacity to elicit ICD. When ICD occurs, immunostimulatory molecules 
collectively called damage associated molecular patterns (DAMPs) are released from or 
displayed by the dying cell [78]. Figure 2b demonstrates the proposed mechanism of NTP-
induced ICD. Several surrogate markers suggestive of ICD can be detected both in vitro 
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and in vivo [78, 79]. These surrogate markers, or critical DAMPs, include surface-
expressed calreticulin (ecto-CRT), secreted ATP, high mobility group box 1 (HMGB1), 
heat shock protein 70 (HSP70), heat shock protein 90 (HSP90), and type I interferons 
(IFNs) [78, 80]. These molecules are harmless when inside the cell and perform vital 
functions for maintaining cellular integrity and function. They become immunogenic only 
when outside the cell, whether membrane-bound or released. Once externalized, DAMPs 
initiate an immunologic response by attracting innate cells, also called antigen presenting 
cells (APCs) (e.g., macrophages, dendritic cells) to the tumor. ATP and HMGB1 act as 
“find me” signals for APCs and chemotactically recruit APCs to the area of DAMP 
emission. Ecto-CRT acts as an “eat me” signal for APCs, promoting phagocytosis of 
DAMP-emitting cells and thus causing activation of APCs. The activated APCs travel to 
lymphatic organs and present tumor antigens to T cells resulting in the expansion of 
effector and memory T cells that are specific for that tumor [78, 80].  
 
In vitro emission of DAMPs serves as a useful indicator of ICD. However, the gold 
standard for verifying the functional ICD notably requires a vaccination protocol involving 
immunocompetent animal models and syngeneic cancer cells [78] (Figure 3). This 
vaccination protocol involves in vitro exposure of malignant cells to an ICD inducer under 
evaluation. Following thorough washing of malignant cells to remove the ICD-inducing 
agent but not the DAMPs, these dying malignant cells are inoculated subcutaneously into 
a flank of immunocompetent mice. One week later, the mice are challenged with 
subcutaneous inoculation of the same living malignant cells in the opposite flank. The mice 
are then monitored for development of subcutaneous tumors at the challenge site. The 
proportion of mice that do not develop tumors at the challenge site reflects the 
immunogenicity of cell death induced by the ICD agent being tested [78]. NTP has now 
emerged as a bona fide ICD inducer. [67, 81] 
 12 
 
Existing inducers of ICD have drawbacks as well as advantages. Although ICD-
mediated immuno-stimulatory effects of radiation have been identified, there is little 
evidence of direct immune cell stimulation. To the contrary, immune cells are highly 
radiosensitive [1, 82]. Additionally, there is mounting evidence suggesting that RT can 
contribute to reversion of the tumor suppressive barriers of the tumor microenvironment 
[83]. Similarly, while PDT is an ICD inducer, it has also been linked to immunosuppression 
in mice and occurrence of late metastases in patients [84]. 
Similar to RT and PDT, NTP is an attractive candidate as an ICD inducer with the 
added benefit of stimulating, or at the very least, preserving immune cells. NTP for cancer 
treatment would compete in this landscape and the comparison is summarized in Table 
2. NTP is unique in that it induces ICD in tumor cells and simultaneously stimulates 
immune cells at the same treatment regimen. Studies have demonstrated enhanced 
migratory activity in macrophages exposed to NTP in vitro [1, 66]. Furthermore, increased 
macrophage-mediated, tumor cell killing of radioresistant, human CNE-1 nasopharyngeal 
carcinoma cells subsequent to NTP exposure has been demonstrated [1, 65]. Thus, NTP 
may confer a significant advantage over RT, PDT, and other ICD inducers that have 
demonstrated concomitant immunosuppression. Further work is required to confirm and 
characterize this direct immunostimulatory effect of NTP within plasma-exposed tumors. 
 
In vitro and In vivo data demonstrating NTP-induced ICD 
NTP-induced ICD has been investigated in vitro in lung cancer and 
nasopharyngeal carcinoma via detection of DAMPs, which are surrogate markers of ICD. 
Specifically, intracellular ROS-induced expression of DAMPs (ecto-CRT and ATP) was 
shown in human A549 lung carcinoma cells and human CNE-1 nasopharyngeal 
carcinoma cells [65, 68]. In addition, there was simultaneous activation of anti-tumor 
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effects of macrophages. This was evidenced by trans-well experiments demonstrating 
increased CNE-1 cell loss when CNE-1 cells were co-cultured with plasma-exposed 
macrophages [65]. Tumor cell toxicity and immunogenicity were also demonstrated 
following exposure to NTP in cultured murine metastatic B16F10 melanoma cells [70]. In 
this study, NTP treatment resulted in decreased metabolic activity, decelerated cell 
growth, and increased cell death. Immunogenicity was confirmed by expression of 
surrogate ICD markers, including major histocompatibility complex I, ecto-CRT, and 
melanocortin receptor I [70]. ICD resulting from NTP treatment has also been 
demonstrated in vitro in CT26 colon cancer cells. These cells were found to undergo 
apoptosis accompanied by calreticulin externalization upon exposure to NTP [69]. Studies 
with newer plasma devices and diverse treatment regimens are ongoing in many 
laboratories around the world to induce ICD in different tumor cell types. 
 
In vivo investigations of the anticancer capacity of NTP have been undertaken for 
brain cancer, skin cancer, breast cancer, colorectal cancer, lung cancer, cervical cancer, 
leukemia, head and neck cancer, and hepatoma [12]. The role of ICD in plasma-mediated 
cancer immunotherapy has been specifically investigated in multiple studies using murine 
models. These studies have introduced a novel paradigm of plasma onco-immunotherapy 
to engage the immune system via ICD induction.  In the seminal study demonstrating NTP-
induced ICD in vivo, a CT26 murine colorectal tumor model was employed [67]. The 
generation of DAMPs (ATP and externalized-CRT) along with recruitment of APCs to the 
tumor area was clearly demonstrated. Most importantly, the capacity of NTP to function 
as a bona fide ICD inducer using the prescribed vaccination protocol was demonstrated. 
This vaccination assay demonstrated protective immunity against CT26 tumor challenge 
in Balb/c mice immunized with NTP-treated CT26 cells. Ninety percent of the mice in the 
plasma-immunized group had tumor volumes smaller than the mean tumor volume of the 
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control group. Furthermore, three of the ten mice in the plasma-immunized group did not 
develop subcutaneous tumors at the challenge site, signifying complete protection [67]. 
This vaccination protocol has also been successfully employed in a melanoma 
mouse model [85]. C57BL/6 mice were vaccinated with melanoma cells treated with DBD 
plasma. Of the eight mice in the NTP-treated group, five were completely protected 
against challenge with live tumor cells, comparable to cells treated with a known ICD-
inducer (Mitoxantrone) [85]. Furthermore, it was demonstrated that the observed ICD-
inducing effects of DBD plasma were from the short-lived ROS (e.g. OH, NO, O/O) 
produced, and not from more persistent species (H2O2, NO2-, NO3-, ONOO-). Vaccines 
created with equivalent amounts of persistent species did not significantly improve 
protection of mice against tumor challenge (37.5%) compared to the negative control 
group (25%) [85]. These two in vivo studies offer conclusive evidence that direct 
application of NTP induces ICD in multiple cancer cell lines of different tissue origins. 
Similar observations have been reported with the perfusion of plasma-activated liquids in 
the abdominal cavities of mice bearing metastatic pancreatic cancer masses [27, 53]. 
Here, the effect is largely due to the more stable species, in contrast to the observations 
of Lin et al [85]. In-depth, mechanistic studies and longitudinal studies to determine the 
effect on disease progression/remission and animal survival are needed. Further 
investigations into plasma delivery and administration protocols with other cancer-cell 
lines are also warranted for potential clinical translation. 
 
Clinical translation of NTP 
Modern approaches to cancer treatment include multimodality strategies that 
typically involve combinations of surgery, radiation, systemic chemotherapy, and more 
recently, immunotherapy. These therapeutic modalities are frequently associated with 
minimal or incomplete treatment responses, disease progression/recurrence, inherent 
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toxicity, and limited patient survival. NTP provides an important platform, rationale, and 
applicability in the arena of cancer treatment. We propose several avenues for using NTP 
alone as a cancer therapy or in combination with currently available therapeutic strategies. 
Previous applications of NTP in oncology have focused on direct tumor cell killing, 
ignoring NTP’s impact on host immunity. Future studies will extend recent observations to 
further elucidate the immunogenic cascade and therapeutic response induced in the host 
in response to NTP treatment. If successful, NTP can provide a safer alternative or adjunct 
to existing ICD mediators, such as RT, chemotherapy, and PDT. NTP used in conjunction 
with current therapeutic strategies may synergistically increase antitumor responses, 
hence decreasing therapeutic levels of chemotherapy administered (dose sparing) while 
converting ICD transforming “cold” metastatic lesions into inflammatory “hot” spots prone 
to immune recognition and tumor immunity. The therapeutic potential of NTP is particularly 
promising in the treatment of cancers refractory to conventional therapies due to 
development of resistance. 
Another challenge faced by the clinician is the all-too-often clinical scenario of 
patients with unresectable or borderline resectable locally advanced tumors. We propose 
that NTP can potentially transition/downstage these tumors to resectable tumors making 
patients better candidates for operative removal. To accomplish this, NTP can be directly 
applied to tumors both by laparoscopic and robotic as well as open laparotomy 
approaches for in situ delivery and treatment. Additionally, NTP may be used to directly 
treat microscopic positive surgical tumor margins in order to prevent local disease 
recurrence. Moreover, after surgical resection, NTP may also be applied indirectly to treat 
clinically occult micro metastatic peritoneal and serosal disease bearing surfaces to halt 
significant disease progression. Likewise, indirect application may be used in the case of 
peritoneal metastases whereby NTP-treated peritoneal fluid is infused into the peritoneal 
cavity by placing indwelling catheters, similar to application frequently used for delivery of 
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intraperitoneal chemotherapy. This expanding treatment paradigm may also be applied 
similarly to treating recurrent disease. As our understanding of mechanism of NTP action 




Herein we have summarized the therapeutic potential of NTP application for cancer 
immunotherapy via ICD. Previous applications of NTP in oncology have focused on direct 
anti-cancer (ablative) approaches, ignoring the potential impact of plasma therapy on host 
immunity. NTP-induced ICD can promote lasting immunity against tumor antigens. 
Several animal studies have, in part, elucidated the mechanisms and potential efficacy of 
this approach. Further evaluation of mechanism of action of NTP, optimization of NTP 
devices, clinical delivery systems, and treatment protocols, will facilitate application of 














































































































































































































































































































Non-Thermal Plasma Induced Immunogenic Cell Death in Cancer: A Topical Review 
In Vivo In Vitro Plasma Source Used Article  
Benign Melanocytic 
Tumors   Ar Plasma Jet Yajima et al  
Bladder Ca   He Plasma Jet Keidar et al 
Breast   He Plasma Jet Mirpour et al 
  Breast He Plasma Jet Mirpour et al 
  Breast He Plasma Jet Wang et al 
  Cervical  Microplasma Jet Device Tan et al 
  Cervical  Plasma Jet with Air Flow Ahn et al 
  Colorectal Ar Plasma Jet Bekeschus et al 
  Colorectal FE-DBD Vandamme et al 
  Colorectal He Plasma Jet Ishaq et al 
Colorectal Colorectal DBD Lin et al* 
Glioblastoma   FE-DBD Vandamme et al 
  Glioblastoma  DBD  Kaushik et al 
  Glioblastoma  Indirect PAM treated with Ar gas flow Tanaka et al 
Glioblastoma Glioblastoma  FE-DBD Vandamme et al 
  Hepatoma Microplasma Jet Device Tan et al 
  Hepatoma He Plasma Jet Zhao et al 
  HNSCC He Plasma Jet Guerrero-Preston et al 
HNSCC HNSCC He/O2 Plasma Jet Kang et al 
  Leukemia Atmospheric Air Plasma System Thiyagarajan et al 
  Leukemia DBD Thiyagarajan et al 
  Lung DBD Lin et al* 
  Lung He Plasma Jet Keidar et al 
  Lung Microplasma Jet Device Kim, JY et al 
Melanoma   DBD Chernets et al 
Melanoma   DBD Lin et al* 
Melanoma   N2/O2 Plasma Jet Mizuno et al  
  Melanoma Ar Plasma Jet Bekeschus et al 
  Melanoma DBD Kim, G et al 
  Melanoma FE-DBD Fridman et al 
Melanoma Melanoma He Plasma Jet Keidar et al 
  Neuroblastoma He Plasma Jet Walk et al 
Ovarian Ovarian Indirect PAM treated Ar Plasma Jet Utsumi et al 
Pancreatic   He Plasma Jet Brulle et al 
  Pancreatic He Plasma Jet Brulle et al 
Pancreatic Pancreatic Direct Ar Plasma Jet, Indirect PAM treated with Ar Plasma Jet Liedtke et al* 
Pancreatic Pancreatic Ar Plasma Jet Pertecke et al 
 
Non-Thermal Plasma Induced Immunogenic Cell Death in Cancer: A Topical Review 
Table 1: Studies Investigating Anti-Cancer Potential of Non-Thermal Plasma (NTP) 
A list of in vivo and in vitro studies reviewed, including type of cancer investigated in each study. 
* indicated studies investigating NTP-induced immunogenic cell death (ICD).  
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NTP- non-thermal plasma, RT- radiation therapy, PDT- photodynamic therapy 
 




  NTP RT PDT 





Yes No  Yes 
Side effects Unknown 




site specific side 
effects caused by 





Oxidative stress [13] DNA breakage [82] Oxidative stress, damage 




Superficial Deep Superficial 






Suppressive [82] Suppressive [84] 
Non-Thermal Plasma Induced Immunogenic Cell Death in Cancer: A Topical Review 
Fig 1: Current Immunotherapy Approaches: When the T cell receptor encounters a foreign 
antigen presented in the MHC cleft of an APC, several checks and balances are put in place to 
avoid inappropriate immune responses. T cell proliferation and activation occurs only if the next 
step of CD28 (a co-stimulatory molecule) binding with B7 ensues. CTLA4 is another natural ligand 
for B7 but this binding does results in T cell inhibition. It is the fine-tuned balance between 
CD28/B7 and CTLA4/B7 that determines the activated (T cell on) and inactivated (T cell off) status 
and hence the nature of immune responses. PD1 is another negative regulator of T cell function 
that functions later during an immune response. Another approach being used in the clinic is the 
production of genetically engineered T cells (CAR T cells) that are designed to attack specific 
tumor antigens. (MHC, major histocompatibility complex; APC, antigen presenting cell) 
 
 
1a: Cytotoxic T Lymphocyte Associated Protein 4 (CTLA4) Blockade 
CTLA4 functions as a checkpoint during immune responses to foreign antigens by sending 
inhibitory signals and down regulating T cell responses. This function is necessary for preventing 
autoimmunity. Normally, T-cell activation is attenuated by the regulatory mechanism of CTLA4/B7 
interaction (T cell OFF). Release of negative regulation by using anti-CTLA4 antibodies is 
achieved by making CTLA4 unavailable for B7 interaction (T cell ON). 
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1b: Programmed Death 1/ Programmed Death – Ligand 1 Blockade 
T-cell proliferation and activation is attenuated by the normal regulatory mechanisms of PD-1/PD-
L1 interaction (T cell OFF). PD1 expression is a hallmark of T cell exhaustion. When this 
interaction is blocked by antibodies, these inhibitory signals are overcome and the T cell becomes 
functional again (T cell ON). 
 
 
1c: Chimeric Antigen Receptor-T Cell Production 
CARs are fusion proteins consisting of antigen recognition domain and T cell signaling domain. T 
cells can be made to express CARs, resulting in a targeted anti-cancer immune response. The 
antigen-recognizing variable regions (scFVs) are from monoclonal antibodies (mAB) with an 
intracellular T-cell signaling domain. The CD3 ζ chain of the T-cell receptor (TCR) was used in 
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first generation receptors. Second and third generation receptors utilize costimulatory signals 
such as CD28 or 4-1 BB (which is derived from the TNF family). CARs are then inserted into T-
cells via a retrovirus-mediated gene transfer. 
  




Figure 2a: Potential Action of Non-thermal Plasma (NTP) in Cancer Immunotherapy 
NTP via proposed exposure both directly stimulates immune cells and induces immunogenic cell 
death. Immunogenic cell death (Ref 28, 67, 85) results in recruitment and stimulation of APC 
(antigen presenting cells) (Ref 28, 67, 85), memory cell formation, and T-cell development (Ref 
67, 85). These circulating cells can then target other non-NTP exposed metastatic tumors of the 
same origin. 




Figure 2b: Proposed Mechanism of Non-thermal Plasma Induced Immunogenic Cell Death 
(ICD) 
Immunogenic cell death is a specific cell death mechanism that stimulates cells of the adaptive 
immune system. When ICD occurs, damage associated molecular patterns (DAMPs) are emitted; 
calreticulin is externalized on the cell membrane and ATP, HMGB1, and HSPs (heat shock 
proteins 70 and 90) are released by the dying cell (Ref 65, 67, 68, 69, 70). These DAMPs then 
initiate an immunologic response by attracting innate dendritic cells to the tumor. DAMPs also aid 
in the maturation of antigen carrying dendritic cells, resulting in a tumor-specific immune response 
by activated T cells (Ref 28, 67). 
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Figure 3: Validation of Non-Thermal Plasma-Induced (NTP) ICD Using a Vaccination 
Protocol 
Vaccination protocol demonstrating protective immunity against a tumor challenge in mice 
immunized with non-thermal plasma (NTP) treated tumor cells. Vaccination with tumor cells 
undergoing ICD causes development of a robust, protective immune response against the specific 
tumor in the animals. When challenged with live tumor cells at a different site, none or smaller 
tumor nodes should be observed, if the vaccination was successful. In mice immunized with NTP 
treated tumor cells, several animals developed no tumors. Of those that did, a significantly smaller 
mean tumor volume at the distal challenge site was observed as compared to the control group. 
